The Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2 pipeline drugs market research report outlays comprehensive information on the Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Central Nervous System which include the indications Solid Tumor, Melanoma, and Alzheimer’s Disease. It also reviews key players involved in Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2 pipeline targets constitutes close to 18 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 4, 5, 7, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2 overview
Leukocyte immunoglobulin like receptor subfamily B member 2 (LILRB2) is a member of the leukocyte immunoglobulin-like receptor (LIR) family and belongs to the subfamily B class of LIR receptors, which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity.
For a complete picture of Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
